AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV): $109.14

0.38 (+0.35%)

POWR Rating

Component Grades














  • ABBV scores best on the Value dimension, with a Value rank ahead of 92.89% of US stocks.
  • ABBV's strongest trending metric is Growth; it's been moving up over the last 52 weeks.
  • ABBV's current lowest rank is in the Momentum metric (where it is better than 18.97% of US stocks).

ABBV Stock Summary

  • ABBV has a market capitalization of $192,198,010,860 -- more than approximately 98.89% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 10.96 for AbbVie Inc; that's greater than it is for 93.34% of US stocks.
  • In terms of volatility of its share price, ABBV is more volatile than just 3.28% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AbbVie Inc are NVS, TXN, AZN, SAP, and CSCO.
  • ABBV's SEC filings can be seen here. And to visit AbbVie Inc's official web site, go to

ABBV Valuation Summary

  • ABBV's EV/EBIT ratio is 33.9; this is 15.7% higher than that of the median Healthcare stock.
  • ABBV's EV/EBIT ratio has moved up 18.8 over the prior 105 months.
  • ABBV's price/earnings ratio has moved up 15.8 over the prior 105 months.

Below are key valuation metrics over time for ABBV.

Stock Date P/S P/B P/E EV/EBIT
ABBV 2021-08-31 4.0 17.0 32.0 33.9
ABBV 2021-08-30 4.0 17.0 32.0 33.8
ABBV 2021-08-27 3.9 16.8 31.7 33.6
ABBV 2021-08-26 4.0 16.9 31.9 33.8
ABBV 2021-08-25 4.0 16.9 31.9 33.8
ABBV 2021-08-24 3.9 16.8 31.7 33.6

ABBV Growth Metrics

  • Its year over year price growth rate is now at 37.86%.
  • Its 4 year price growth rate is now at 34.31%.
  • The 2 year revenue growth rate now stands at 15.01%.
Over the past 30 months, ABBV's revenue has gone up $20,976,000,000.

The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 53,729 20,451 6,663
2021-03-31 50,195 18,650 5,159
2020-12-31 45,804 17,588 4,616
2020-09-30 40,650 16,009 7,381
2020-06-30 36,227 14,734 6,957
2020-03-31 34,057 14,122 8,436

ABBV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABBV has a Quality Grade of B, ranking ahead of 77.3% of graded US stocks.
  • ABBV's asset turnover comes in at 0.359 -- ranking 134th of 681 Pharmaceutical Products stocks.
  • CAPR, HSTO, and BCDA are the stocks whose asset turnover ratios are most correlated with ABBV.

The table below shows ABBV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.359 0.656 0.102
2021-03-31 0.335 0.648 0.078
2020-12-31 0.339 0.664 0.070
2020-09-30 0.339 0.687 0.131
2020-06-30 0.372 0.736 0.147
2020-03-31 0.459 0.774 0.207

ABBV Stock Price Chart Interactive Chart >

Price chart for ABBV

ABBV Price/Volume Stats

Current price $109.14 52-week high $121.53
Prev. close $108.76 52-week low $79.11
Day low $108.31 Volume 4,614,300
Day high $109.22 Avg. volume 6,961,976
50-day MA $111.36 Dividend yield 4.76%
200-day MA $111.27 Market Cap 192.87B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 22, 2021

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Yahoo | October 22, 2021

AbbVie and More Companies That Are Expected to Raise Their Dividends

The financial data firm IHS Markit says the biopharmaceutical company, Visa, and West Pharmaceutical Services are likely to boost their payouts.

Yahoo | October 22, 2021

Progenity Has Seven Quarters Left to Reverse Its Burn Rate

Progenity has a plan in place to save $97 million a year, but how fast can they pull it off, and will it be enough to save PROG stock?

Mark R. Hake on InvestorPlace | October 21, 2021

7 Dividend Stocks To Buy for 2022 and Hold Forever

Buy these dividend stocks and forget them for 10 years, you will win big and should have little to worry about in the interim.

Alex Sirois on InvestorPlace | October 20, 2021

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo 3.17%
3-mo -6.36%
6-mo -0.21%
1-year 35.61%
3-year 57.85%
5-year 125.07%
YTD 6.74%
2020 27.72%
2019 1.47%
2018 -0.96%
2017 60.08%
2016 9.79%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8863 seconds.